A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma

C. R. Crawley, J. M. Foran, R. K. Gupta, A. Z.S. Rohatiner, K. Summers, J. Matthews, I. N.M. Micallef, J. A. Radford, S. A. Johnson, P. W. Johnson, J. W. Sweetenham, T. A. Lister

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Background: 'Molecular response' is being investigated as a therapeutic goal in follicular lymphoma (FL). High response rates in FL with the fludarabine combination 'FMD' have been associated with 'molecular remission'. A phase II study of FMD in FL was therefore conducted. Patients and methods: Fifty-four patients, ten of whom were newly diagnosed received FMD. Forty-four percent of the previously treated patients had 'chemoresistant' disease. Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. Blood/bone marrow was collected for quantitation of t(14;18) by 'real-time' PCR. Results: The overall response rate was 37 of 54 (69%), complete responses being seen in 11 patients (20%), with no difference between newly diagnosed and the previously treated patients. However, the response rate in 'chemosensitive' relapse was 84%, compared to 44% in patients in whom the last prior regimen had failed. Molecular responses were seen in 17 of 25 and PCR negativity in 8 of 25, although molecular and clinical responses did not always correlate. Toxicity was moderate, 19 patients required admission. However, in 6 of 12 patients, subsequent G-CSF mobilised stem cell harvests failed. Conclusions: FMD was well tolerated but with a lower than expected response rate. Molecular responses were seen in the majority of responding patients however, 'molecular remission' was rare.

Original languageEnglish (US)
Pages (from-to)861-865
Number of pages5
JournalAnnals of Oncology
Volume11
Issue number7
DOIs
Publication statusPublished - Sep 23 2000
Externally publishedYes

    Fingerprint

Keywords

  • Fludarabine
  • Follicular lymphoma
  • Real time PCR

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Crawley, C. R., Foran, J. M., Gupta, R. K., Rohatiner, A. Z. S., Summers, K., Matthews, J., ... Lister, T. A. (2000). A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Annals of Oncology, 11(7), 861-865. https://doi.org/10.1023/A:1008381105849